{"id":130846,"date":"2026-07-08T14:50:18","date_gmt":"2026-07-08T20:50:18","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=130846"},"modified":"2026-07-08T14:50:18","modified_gmt":"2026-07-08T20:50:18","slug":"what-is-cagrilintide-the-amylin-analog-behind-cagrisema","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/what-is-cagrilintide-the-amylin-analog-behind-cagrisema\/","title":{"rendered":"What Is Cagrilintide? The Amylin Analog Behind CagriSema"},"content":{"rendered":"

Cagrilintide is a once-weekly injectable weight-loss drug that works through amylin, a satiety hormone that’s completely separate from the GLP-1 pathway most obesity drugs use. Developed by Novo Nordisk, it’s best known as the amylin half of CagriSema (the cagrilintide-plus-semaglutide combination), but it’s also being studied on its own. It’s investigational and not FDA approved. On its own it produced about 10.8% weight loss in a mid-stage trial. Understanding cagrilintide helps make sense of where obesity treatment is heading beyond GLP-1s.<\/p>\n

A Different Hormone Entirely<\/h3>\n

Amylin is a hormone your pancreas releases alongside insulin when you eat. It does several useful things: it slows stomach emptying, tells your brain you’re full (acting on satiety centers in the hindbrain), and helps restore sensitivity to leptin (another fullness hormone). This is a genuinely different mechanism from GLP-1 drugs, which primarily reduce appetite through separate pathways.<\/p>\n

The problem with natural amylin is that it’s unstable and clumps together, which is why an older amylin-based drug (pramlintide) had to be injected multiple times a day. Cagrilintide was engineered to solve that, with a structure stable enough to allow once-weekly dosing. That single change turned amylin from an impractical option into a viable once-weekly therapy.<\/p>\n

Why Amylin Matters for Weight Loss<\/h3>\n

Because amylin works through a different pathway than GLP-1, the two can be combined for an additive effect, which is the whole rationale behind CagriSema. Two appetite-regulating hormones with non-overlapping receptor systems should, in theory, produce more weight loss together than either alone. Cagrilintide is the piece that brings the amylin mechanism to that combination.<\/p>\n

On its own, cagrilintide has shown solid results. A dose-finding phase 2 trial published in The Lancet<\/a> in 2021 tested once-weekly cagrilintide in more than 700 adults with overweight or obesity and found that the highest dose produced about 10.8% weight loss at 26 weeks, versus roughly 3% with placebo, and that it was well tolerated. The researchers concluded the findings supported developing drugs with novel mechanisms like this one.<\/p>\n

Quick Facts<\/h3>\n
\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Developer<\/td>\nNovo Nordisk<\/td>\n<\/tr>\n
Type<\/td>\nLong-acting amylin analog<\/td>\n<\/tr>\n
Administration<\/td>\nOnce-weekly injection<\/td>\n<\/tr>\n
Status<\/td>\nInvestigational (not FDA approved)<\/td>\n<\/tr>\n
Standalone data<\/td>\nAbout 10.8% weight loss at 26 weeks (phase 2)<\/td>\n<\/tr>\n
Best known as<\/td>\nThe amylin component of CagriSema<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Standalone Versus Combination<\/h3>\n

For a while, Novo Nordisk’s focus was on the CagriSema combination rather than cagrilintide by itself. More recently, analyses of the amylin component have supported advancing cagrilintide as a standalone drug too. Consider a hypothetical patient who doesn’t tolerate GLP-1 drugs well because of nausea. An amylin-based option that works through a different pathway could, in principle, be a useful alternative, which is part of why a standalone amylin drug is worth developing rather than only using it in combination.<\/p>\n

What This Means for You Right Now<\/h3>\n

Cagrilintide is not available, whether on its own or as CagriSema, and TrimRx does not offer it. TrimRx provides medications you can actually access today, including compounded semaglutide and compounded tirzepatide plus brand options like Ozempic, Wegovy, Mounjaro, and Zepbound. If weight loss is your goal now, those are the tools to consider, since cagrilintide remains in development.<\/p>\n

The amylin approach is one of the more interesting directions in obesity medicine, but for the moment it’s a story to follow rather than a treatment to use.<\/p>\n

Frequently Asked Questions<\/h3>\n

Is cagrilintide the same as CagriSema?<\/h4>\n

No. Cagrilintide is a single drug (an amylin analog). CagriSema is a combination product that pairs cagrilintide with semaglutide (a GLP-1 drug). Cagrilintide is the amylin half of that combination and is also being studied on its own.<\/p>\n

How much weight does cagrilintide produce on its own?<\/h4>\n

In its phase 2 monotherapy trial, the highest dose of cagrilintide produced about 10.8% weight loss over 26 weeks. In combination with semaglutide (as CagriSema), the weight loss is greater, since the two hormones work through different pathways.<\/p>\n

Is cagrilintide available or FDA approved?<\/h4>\n

No. Cagrilintide is investigational and not FDA approved for any use. It is only available through clinical trials, and TrimRx does not offer it.<\/p>\n

If you’d rather focus on medications available today, you can explore the options available to you now<\/a> with a licensed provider.<\/p>\n

This information is for educational purposes and is not medical advice. Cagrilintide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Cagrilintide is a once-weekly injectable weight-loss drug that works through amylin, a satiety hormone that’s completely separate from the GLP-1 pathway most obesity drugs…<\/p>\n","protected":false},"author":7,"featured_media":130065,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-130846","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=130846"}],"version-history":[{"count":2,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130846\/revisions"}],"predecessor-version":[{"id":130848,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130846\/revisions\/130848"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/130065"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=130846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=130846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=130846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}